KPV Peptide – User Manual & Dosage Protocol Guide

1

Product Overview

KPV (Lysine-Proline-Valine) is a small tripeptide derived from α-MSH (alpha-melanocyte-stimulating hormone), studied for its anti-inflammatory, immunomodulatory, and wound-healing properties.

Research Applications:

  • Reducing inflammation in tissues
  • Supporting immune system modulation
  • Enhancing wound healing and tissue repair
  • Potential use in dermatological and gastrointestinal research

Disclaimer: KPV peptide is for research and experimental use only. It is not FDA-approved for therapeutic purposes. Consult a qualified healthcare professional before use.

2

Forms Available

Product FormLyophilized Powder – Freeze-dried KPV for reconstitution

Injection Solution – Subcutaneous (SC) or intramuscular (IM) solution after reconstitution

Topical Solution / Gel – Experimental application for wound healing or dermatology studies

3

Mechanism of Action

KPV functions by:

  • Inhibiting pro-inflammatory cytokines, reducing tissue inflammation
  • Supporting immune modulation
  • Enhancing cell migration and tissue repair
  • Potentially reducing oxidative stress in tissues

Effects are primarily observed in preclinical and experimental research.

4

Dosage Protocol (Investigational)

Administration

Subcutaneous (SC) Injection – Typical Dose: 250–500 µg | Frequency: 1–3× per day | Notes: May be used near affected tissue or systemically

Intramuscular (IM) Injection – Typical Dose: 250–500 µg | Frequency: 1–2× per day | Notes: Systemic delivery for research purposes

Topical / Gel Application – Typical Dose: 0.1–1 mg/cm² | Frequency: 1–2× per day | Notes: Local tissue repair and wound healing studies

Cycle Protocol (Investigational)

Initial Phase (1–2 weeks) – Dose: Lower end of dose range | Notes: Assess tolerance

Therapeutic Phase (2–6 weeks) – Dose: Full dose range | Notes: Maximal anti-inflammatory and tissue repair effect

Rest Period (1–2 weeks) – Dose: None | Notes: Allows system to reset before next cycle

Experimental cycles may be repeated 2–3 times per year, depending on research objectives.

5

Reconstitution Instructions (Lyophilized Powder)

Supplies Needed:

  • Sterile bacteriostatic water
  • Sterile syringe
  • Alcohol swabs

Steps:

  1. Clean vial top with alcohol swab.
  2. Add desired volume of bacteriostatic water (e.g., 5 mg peptide + 1 mL water → 5 mg/mL solution).
  3. Swirl gently to dissolve; do not shake.
  4. Store refrigerated (2–8°C).

Use within 2–4 weeks; discard if cloudy or discolored.

6

Administration Guidelines

Subcutaneous Injection (SC)
  1. Select a clean injection site (abdomen, thigh, or upper arm).
  2. Clean site with alcohol swab.
  3. Insert needle at 45° angle.
  4. Inject slowly; apply gentle pressure afterward.
  5. Rotate injection sites to avoid tissue irritation.
Intramuscular Injection (IM)
  1. Select clean muscle site (deltoid, glute, thigh).
  2. Clean site with alcohol swab.
  3. Insert needle at 90° angle; inject slowly.
  4. Apply gentle pressure afterward.
Topical / Gel Application
  • Apply a thin layer to the affected area 1–2× per day.
  • Clean area before application.
  • Cover with sterile dressing if required for research purposes.
7

Storage Guidelines

Storage Information

Lyophilized Powder – Storage: Cool, dry place | Shelf Life: Up to 12 months

Reconstituted Solution – Storage: Refrigerate 2–8°C | Shelf Life: 2–4 weeks

Topical / Gel – Storage: Refrigerate or room temperature | Shelf Life: 1–3 months

Discard solution if cloudy, discolored, or containing particulates.

8

Safety & Precautions

  • Not recommended for pregnant or breastfeeding women
  • Avoid if allergic to peptides
  • Mild side effects: injection site irritation, redness, or mild itching
  • Discontinue if severe adverse reactions occur
  • Keep out of reach of children

Human clinical data are limited; effects are investigational.

9

Quick Reference Cycle Chart (Investigational)

Weekly Dosing Schedule

Week 1–2 – Dose: 250 µg SC/IM 1× per day | Notes: Initial tolerance phase

Week 3–4 – Dose: 250–500 µg SC/IM 1–2× per day | Notes: Therapeutic phase

Week 5–6 – Dose: 500 µg SC/IM 2–3× per day | Notes: Full effect cycle

Week 7+ – Dose: Rest 1–2 weeks | Notes: Reset before next cycle

10

Visual Guide

  • Diagrams of SC and IM injection sites (abdomen, thigh, arm, deltoid, glute)
  • Step-by-step reconstitution guide
  • Topical application illustration
  • Safety icons for handling, storage, and injections